Novacyt launches product to tell difference between COVID-19 and winter flu

PARIS, Aug 27 (Reuters) - Clinical diagnostics company Novacyt ALNOV.PA, NCYT.L - one of many healthcare companies whose shares have surged during the pandemic - announced on Thursday a new product to allow people to differentiate the COVID-19 virus from common winter diseases.

Novacyt said its new 'Winterplex' test panel includes two gene targets specific to COVID-19, as well as gene targets for influenza A&B and respiratory syncytial virus (RSV).

"We believe Winterplex™ is one of the world’s first approved respiratory test panels that can differentiate between COVID-19 and other common respiratory diseases," Novacyt CEO Graham Mullis said.

(Reporting by Sudip Kar-Gupta; editing by Jason Neely)

((; +33 1 49 49 53 84;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.